Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133 (+) Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy.
According to the European Medicine Agency (EMA) regulatory frameworks, Advanced Therapy Medicinal Products (ATMP) represent a new category of drugs in which the active ingredient consists of cells, genes, or tissues. ATMP-CD133 has been widely investigated in controlled clinical trials for cardiovas...
| Publicado en: | BioMed Research International Vol. 2015; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
10/1/2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |